Marshall Wace North America’s Alnylam Pharmaceuticals ALNY Stock Holding History

Marshall Wace North America’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-108,585	Closed	-$18.4M	–	1407
2021 Q2	$18.4M	Buy	+108,585	New	+$15.9M	0.08%	269
2021 Q1	–	Sell	-150,004	Closed	-$19.5M	–	1480
2020 Q4	$19.5M	Sell	150,004 -92,656	-38%	-$12.4M	0.09%	260
2020 Q3	$35.3M	Sell	242,660 -69,179	-22%	-$9.83M	0.23%	117
2020 Q2	$46.2M	Buy	311,839 +19,090	+7%	+$2.57M	0.31%	86
2020 Q1	$31.9M	Buy	292,749 +125,891	+75%	+$14.5M	0.24%	117
2019 Q4	$19.2M	Buy	+166,858	New	+$16.6M	0.09%	206
2019 Q3	–	Sell	-181,395	Closed	-$13.2M	–	1295
2019 Q2	$13.2M	Buy	+181,395	New	+$13.9M	0.08%	206
2018 Q3	–	Sell	-26,553	Closed	-$2.62M	–	901
2018 Q2	$2.62M	Buy	+26,553	New	+$2.63M	0.01%	696
2017 Q2	–	Sell	-8,767	Closed	-$447K	–	1277
2017 Q1	$447K	Buy	+8,767	New	+$405K	﹤0.01%	829
2013 Q3	–	Sell	-87,828	Closed	-$2.72M	–	607
2013 Q2	$2.72M	Buy	+87,828	New	+$2.34M	0.21%	147

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace North America's ALNY Position: Q3 2021 in Review

Marshall Wace North America sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2021, closing a stake of 108,585 shares — an estimated $18.4M sold.

Marshall Wace North America first reported a position in ALNY in Q2 2013 and held it in 10 quarters. The position peaked at $46.2M in Q2 2020. 405 funds tracked by Wall St. Rank hold ALNY as of Q3 2021.

Marshall Wace North America reported no remaining Alnylam Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Marshall Wace North America sold 108,585 Alnylam Pharmaceuticals shares in Q3 2021, an estimated $18.4M.
Marshall Wace North America first reported a position in Alnylam Pharmaceuticals in Q2 2013 and held it in 10 quarters.
Marshall Wace North America's Alnylam Pharmaceuticals position peaked at $46.2M in Q2 2020.
405 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.